278 related articles for article (PubMed ID: 25979279)
1. Pneumococcal vaccination in older adults in the era of childhood vaccination: Public health insights from a Norwegian statistical prediction study.
Steens A; Vestrheim DF; de Blasio BF
Epidemics; 2015 Jun; 11():24-31. PubMed ID: 25979279
[TBL] [Abstract][Full Text] [Related]
2. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
3. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
[TBL] [Abstract][Full Text] [Related]
4. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.
Kim JH; Chun BC; Song JY; Kim HY; Bae IG; Kim DM; Choi YH; Jun YH; Choi WS; Kang SH; Kwon HH; Jeong HW; Kee SY; Hur J; Chung JW; Yoon YK; Sohn JW; Yang KS; Kim MJ
Vaccine; 2019 May; 37(21):2797-2804. PubMed ID: 31005428
[TBL] [Abstract][Full Text] [Related]
5. Rethinking number-needed-to-vaccinate for pneumococcal conjugate vaccines in older adults: Current and future implications.
McLaughlin JM; Swerdlow DL; Isturiz RE; Jodar L
Vaccine; 2017 Sep; 35(40):5360-5365. PubMed ID: 28863866
[TBL] [Abstract][Full Text] [Related]
6. Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan.
Su WJ; Chuang PH; Chang LY; Lo HY; Chiang CS; Wang ET; Yang CH
BMC Infect Dis; 2021 Jan; 21(1):45. PubMed ID: 33423657
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.
Rudnick W; Liu Z; Shigayeva A; Low DE; Green K; Plevneshi A; Devlin R; Downey J; Katz K; Kitai I; Krajden S; Ostrowska K; Richardson D; Richardson S; Sarabia A; Silverman M; Simor AE; Tyrrell G; McGeer A;
Vaccine; 2013 Dec; 31(49):5863-71. PubMed ID: 24099873
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
Jiang Y; Gauthier A; Keeping S; Carroll S
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):913-27. PubMed ID: 25189087
[TBL] [Abstract][Full Text] [Related]
9. Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
Dunne EM; Cilloniz C; von Mollendorf C; Lewnard J; Grant LR; Slack MPE; Jodar L; Theilacker C; Gessner BD
Arch Bronconeumol; 2023 Mar; 59(3):157-164. PubMed ID: 36681604
[TBL] [Abstract][Full Text] [Related]
10. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults.
Atwood M; Beausoleil L; Breton MC; Laferriere C; Sato R; Weycker D
Can J Public Health; 2018 Dec; 109(5-6):756-768. PubMed ID: 29981104
[TBL] [Abstract][Full Text] [Related]
13. A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany.
Jiang Y; Gauthier A; Annemans L; van der Linden M; Nicolas-Spony L; Bresse X
Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):631-43. PubMed ID: 23025421
[TBL] [Abstract][Full Text] [Related]
14. Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales.
Ladhani SN; Andrews NJ; Waight P; Borrow R; Slack MP; Miller E
Clin Infect Dis; 2014 Feb; 58(4):517-25. PubMed ID: 24300040
[TBL] [Abstract][Full Text] [Related]
15. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.
Andrews NJ; Waight PA; George RC; Slack MP; Miller E
Vaccine; 2012 Nov; 30(48):6802-8. PubMed ID: 23000122
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis.
Kraicer-Melamed H; O'Donnell S; Quach C
Vaccine; 2016 Mar; 34(13):1540-1550. PubMed ID: 26899372
[TBL] [Abstract][Full Text] [Related]
17. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
American Academy of Pediatrics Committee on Infectious Diseases
Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium.
Willem L; Blommaert A; Hanquet G; Thiry N; Bilcke J; Theeten H; Verhaegen J; Goossens H; Beutels P
Hum Vaccin Immunother; 2018 May; 14(5):1218-1229. PubMed ID: 29420161
[TBL] [Abstract][Full Text] [Related]
19. A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
Jiang Y; Gauthier A; Keeping S; Carroll S
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):901-11. PubMed ID: 25186657
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
